References
- Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88:167–179.
- Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–2269.
- Jung G, Metelitsa A, Dover D, et al. Trends in incidence of nonmelanoma skin cancers in Alberta, Canada from 1988 through 2007. Br J Dermatol. 2010;163:146–154.
- Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management: developed by the guideline subcommittee of the European Dermatology Forum. Eur J Dermatology. 2014;24:312–329.
- Callens J, Van Eycken L, Henau K, et al. Epidemiology of basal and squamous cell carcinoma in Belgium: the need for a uniform and compulsory registration. J Eur Acad Dermatol Venereol. 2016;30:1912–1918.
- Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–754.
- Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90–92.
- Rezakovic S, Zuzul K, Kostovic K. Basal cell carcinoma: review of treatment modalities. J Dermatology Clin Res. 2014;2:1035.
- Koury J, Zhong L, Hao J. Targeting signaling pathways in cancer stem cells for cancer treatment. Stem Cells Int. 2017;2017:1.
- Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma. JAMA Dermatol. 2016;152:816.
- Tang N, Ratner D. Implementation of systemic hedgehog inhibitors in daily practice as neoadjuvant therapy. J Natl Compr Canc Netw. 2017;15:537–543.
- Association WM.WMA declaration of Helsinki - ethical principles for medical research involving human subjects; 2013. (June 1964):1–8.
- Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015;17:497–503.
- Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111:1476–1481.
- Lear JT, Basset-Seguin N, Kaatz M, et al. Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review. Eur J Dermatol. 2017;27:386–392.
- Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015;73:99–105.
- Alcalay J, Tauber G, Fenig E, et al. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol. 2015;14:219–223.
- Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:1–10.
- Paulsen JF, Øregaard JS, Nielsen AL, et al. Vismodegib and surgery combined – effective treatment of locally advanced basal cell carcinoma. Acta Oncol (Madr). 2016;55:1492–1494.
- Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71:904–911.
- Maier T, Kulichova D, Ruzicka T, et al. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. J Am Dermatology. 2014;71:725–730.
- Caresana G, Giardini R. Dermoscopy-guided surgery in basal cell carcinoma. J Eur Acad Dermatol Venereol. 2010;24:1395–1399.
- Couzan C, Cinotti E, Labeille B, et al. Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment. J Eur Acad Dermatology Venereol. 2017;12:3218–3221.